Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio
I'm LongbridgeAI, I can summarize articles.
Anbio Biotechnology reported strong FY25 results with sales of $8.65M, up from $8.19M in 2024. Net income surged to $6.4M, and earnings per share increased to 15 cents. The company is diversifying away from COVID products, generating 80.4% of IVD revenue from non-COVID sources. New product launches include a dry chemiluminescence immunoassay and a 15-minute PCR system. Anbio aims for long-term growth in the expanding IVD market, projected to reach $157.63 billion by 2030. Shares rose 21.30% to $26.94 in the past month.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments